Retrophin (NASDAQ:RTRX) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.27), Morningstar.com reports. Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The company had revenue of $44.71 million for the quarter, compared to the consensus estimate of $43.01 million. During the same quarter in the prior year, the firm earned ($0.25) earnings per share. Retrophin’s revenue for the quarter was up 8.2% compared to the same quarter last year.
Shares of Retrophin stock opened at $19.24 on Wednesday. The company has a current ratio of 4.57, a quick ratio of 4.52 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $20.41. Retrophin has a 52 week low of $17.53 and a 52 week high of $33.00. The company has a market capitalization of $788.54 million, a PE ratio of -7.57 and a beta of 0.90.
In other Retrophin news, insider William E. Rote sold 1,625 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $17.77, for a total transaction of $28,876.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Laura Clague sold 2,500 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $18.25, for a total value of $45,625.00. Following the sale, the chief financial officer now owns 14,750 shares in the company, valued at approximately $269,187.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,319 shares of company stock worth $244,378. 4.32% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on the stock. BidaskClub cut shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Thursday, July 25th. Canaccord Genuity lifted their price objective on shares of Retrophin from $37.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, July 1st. Zacks Investment Research upgraded shares of Retrophin from a “sell” rating to a “hold” rating in a research report on Wednesday, July 10th. Barclays started coverage on shares of Retrophin in a research report on Monday, April 22nd. They issued an “overweight” rating and a $36.00 price target on the stock. Finally, William Blair reiterated a “buy” rating on shares of Retrophin in a research report on Friday, July 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $44.50.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Read More: Benefits of owning preferred stock
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.